Patents Examined by Karen Cochrane Carlson
  • Patent number: 11898176
    Abstract: Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: February 13, 2024
    Assignee: Duke University
    Inventors: Charles Gersbach, David Ousterout
  • Patent number: 11807899
    Abstract: The invention relates to processes for performing biochemical reactions, such as in an aqueous in vitro reaction system. The processes involve macromolecules, particularly polypeptides, comprising one or more functional intrinsically disordered regions (IDRs). The invention also relates to IDR-macromolecules, including IDR-polypeptides, including macromolecules or polypeptides comprising a tagged amino acid sequence which comprises or consists of one or more functional IDRs. Such functional IDRs are capable of increasing the efficiency of the biochemical reaction. The invention relates to kits comprising any such macromolecules and polypeptides. The invention further relates to processes for stimulating or enhancing liquid-liquid demixing in a solution using any such macromolecules and polypeptides, including in combination with multivalent metal ions, thereby providing reagents capable of increasing the efficiency of a biochemical reaction.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: November 7, 2023
    Inventors: Niall Armes, Hannah Williams, Matthew Forrest, Mathew Parker, Sidong Liu, Lauren Parker
  • Patent number: 11802276
    Abstract: Disclosed are methods for isolating polymerase complexes from a mixture of polymerase complex components. The polymerase complexes can comprise a nanopore to provide isolated nanopore sequencing complexes. The methods relate to the positive and negative isolation of the polymerase complexes and/or nanopore sequencing complexes. Also disclosed is a nucleic acid adaptor for isolating active polymerase complexes, polymerase complexes comprising the nucleic acid adaptor, and methods for isolating active polymerase complexes using the nucleic acid adaptor.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 31, 2023
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Helen Franklin, Cynthia Cech, Timothy Kellogg Craig, Aruna Ayer, Kirti Dhiman, Natalie B. Chechelski Johnston, Joshua N. Mabry, Arkadiusz Bibillo, Peter Crisalli, Randall W. Davis
  • Patent number: 11795212
    Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: October 24, 2023
    Inventors: Donald E. Ingber, Michael Super, Jeffrey Charles Way, Mark J. Cartwright, Julia B. Berthet, Dinah R. Super, Martin Rottman, Alexander L. Watters
  • Patent number: 11780895
    Abstract: Provided herein are, inter alia, compositions and methods for demethylating and methylating a target DNA sequences in a mammalian cell. The compositions and methods are, useful for activity modulation of a targeted gene, or to create a gene regulatory network.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 10, 2023
    Assignee: The Jackson Laboratory
    Inventors: Albert Cheng, Aziz Taghbalout, Nathaniel Jillette
  • Patent number: 11773381
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 3, 2023
    Assignee: Gem Vax & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 11767512
    Abstract: The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 26, 2023
    Inventors: Toni Cathomen, Tatjana Cornu, Philippe Duchateau, Claudio Mussolino, Marianna Romito, Agnes Gouble
  • Patent number: 11738048
    Abstract: Disclosed herein are cells that are immune cells, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, and optionally recombinantly express a chimeric antigen receptor (CAR), wherein the CAR binds to a viral antigen. In certain embodiments, the immune cell is an immunostimulatory cell, such as a T cell. In certain embodiments, the immune cell is an immunoinhibitory cell, such as a regulatory T cell. Also disclosed herein are immune cells that recognize and are sensitized to a viral antigen, which immune cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell. The cells can be sensitized to an antigen that is a viral antigen. Additionally provided are methods of using such cells to treat a viral infection in a subject in need thereof.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: August 29, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventor: Prasad S. Adusumilli
  • Patent number: 11739377
    Abstract: The invention relates to improving the movement of a target polynucleotide with respect to a transmembrane pore when the movement is controlled by a polynucleotide binding protein. The invention also relates to improved transmembrane pores and polynucleotide binding proteins.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: August 29, 2023
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace, Jonathan Bankes Pugh, Richard George Hambley, Neil Roger Wood, Clive Gavin Brown, James White, Andrew John Heron, Mark Bruce, Christopher Peter Youd, Rebecca Victoria Bowen
  • Patent number: 11733246
    Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 22, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Patent number: 11723985
    Abstract: There is provided a phospholipid composition which is a bilayer or micelle comprising at least one embedded protein-polymer surfactant conjugate comprising an anchor protein, wherein the anchor protein is a cationised protein or an anionised protein, the composition characterised in that the anchor protein is: a) an active enzyme; or b) is a protein which does not comprise a —CH2C(O)NCH3(CH2)3NCH3)2H+ linker covalently bonded to an amino acid side chain.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 15, 2023
    Inventors: Adam Willis Perriman, Robert Christopher Deller, Wenjin Xiao, Thomas Iain Phillip Green, Benjamin Michael Carter, Graham John Day, Rosalia Cuahtecontzi Delint
  • Patent number: 11718864
    Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: August 8, 2023
    Assignee: Pfizer Inc.
    Inventors: Gregory Walter Hiller, Jeffrey Joseph Mitchell, Bhanu Chandra Mulukutla, Pamela Mary Pegman
  • Patent number: 11708587
    Abstract: Provided herein are compositions and methods to make and use engineered cells, for the purpose of increasing the cell density of a culture comprising metazoan cells and for the production of a cultured edible product.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: July 25, 2023
    Assignee: UPSIDE FOODS, INC.
    Inventors: Nicholas J. Genovese, Eric N. Schulze, Danielle Nicole Desmet
  • Patent number: 11690874
    Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: July 4, 2023
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Zhejiang University
    Inventors: Lei Xiao, Chengfei Pu, Zhao Wu, Linrong Lu
  • Patent number: 11690880
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: July 4, 2023
    Assignee: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11685772
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: June 27, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Patent number: 11672828
    Abstract: Described herein are polypeptides, systems, and methods that relate to using domains that bind specifically to a biotinylamide to control receptor and cellular activity.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: June 13, 2023
    Inventors: John T. Ngo, Jeffrey Blye McMahan
  • Patent number: 11673941
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 13, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Patent number: 11666641
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: June 6, 2023
    Assignee: EMENDOBIO INC.
    Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
  • Patent number: 11650201
    Abstract: The present invention relates to the field of anastasis, i.e., the process of reversal of apoptosis. More specifically, the present invention provides methods and compositions useful for studying anastasis. The present invention also provides a biosensor comprising (a) a split transcription factor complex comprising one half of a split transcription factor linked to a transmembrane domain via an enzyme cleavable linker; (b) a split transcription factor comprising the other half of the split transcription factor linked to a MTS via an enzyme-cleavable linker; and (c) a reporter system comprising (1) a first nucleic acid encoding a site specific recombinase operably linked to the site specific sequence for the transcription factor; and (2) a second nucleic acid comprising a stop codon cassette flanked by site specific recombination sequences, wherein the split transcription factor is Gal 4 or split Q. In other embodiments, the recombinase is Cre or FLP.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: May 16, 2023
    Assignee: The Johns Hopkins University
    Inventors: Ho Lam Tang, Ho Man Holly Tang